Prostate Cancer Clinical Trials (May 2026): ~900 Recruiting Interventional Studies

Last updated: May 7, 2026

Current Clinical Trial Landscape

Recruiting Trials by Disease Stage

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

ADT + AR-pathway inhibitor ± docetaxel is standard. Trials explore intensification and PSMA-based approaches:

• Triplet therapy / intensification:
  • NCT06931340 - ADT + Apalutamide ± Docetaxel in metastatic prostate cancer (Phase 3)
  • NCT05983783 - Rezvilutamide + ADT + Docetaxel vs Rezvilutamide + ADT in mHSPC (Phase 3)
  • NCT07241416 - Rezvilutamide in mHSPC (Phase 3)
• PSMA-directed in mHSPC:
  • NCT06496581 - PEACE6: SOC ± 177Lu-PSMA-617 in de novo mHSPC with poor PSA response (Phase 3)
• De-escalation:
  • NCT07260435 - Shorter treatment with ARPI in low-volume mHSPC (Phase 3)
• Suboptimal response:
  • NCT06592924 - Adding docetaxel to ARPI in mCSPC with suboptimal PSA response (Phase 3)
• Platform trial:
  • NCT06320067 - Randomised platform trial testing treatments in mHSPC (Phase 3)

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

207 recruiting trials. The most active area of research:

• Bispecific T-cell engagers:
  • NCT06691984 - Xaluritamig (STEAP1×CD3) vs Cabazitaxel or second ARPI (Phase 3)
  • NCT07164443 - Pasritamig (PSMA×CD3) vs Placebo in late-line mCRPC (Phase 3)
  • NCT07225946 - Pasritamig + Docetaxel vs Docetaxel in mCRPC (Phase 3)
• Next-gen AR-targeted:
  • NCT06136650 - Opevesostat (CYP11A1 inhibitor, MK-5684) vs alternative NHA in mCRPC (Phase 3)
  • NCT07028853 - Mevrometostat (EZH2 inhibitor) + Enzalutamide in mCRPC (Phase 3)
  • NCT03851640 - HC-1119 (next-gen anti-androgen) in mCRPC (Phase 3)
• PSMA radioligand:
  • NCT06780670 - AAA817 vs standard of care in previously treated PSMA+ mCRPC (Phase 3)
  • NCT06520345 - ProstACT Global: 177Lu-TLX591 + SOC vs SOC alone in mCRPC (Phase 3)
• HER2-targeted ADC (new):
  • NCT06925737 - Ifinatamab deruxtecan (I-DXd, MK-2400) in metastatic prostate cancer (Phase 3)
• BRCA/HRR-mutated:
  • NCT06120491 - Saruparib (AZD5305) vs Placebo + NHA in mCSPC with BRCA/HRR (Phase 3)
• Platform / biomarker-driven:
  • NCT03903835 - ProBio: Biomarker-driven multi-arm platform trial in metastatic prostate cancer (Phase 3)

Biochemical Recurrence / Oligometastatic

• NCT04794777 - Salvage RT vs PSMA PET/CT-targeted treatment in relapsing prostate cancer (Phase 3)
• NCT05352178 - Metastasis-directed therapy for oligorecurrent prostate cancer (Phase 3)
• NCT04787744 - Standard systemic therapy ± PET-directed local therapy for oligometastatic prostate cancer (Phase 2/3)
• NCT04423211 - Apalutamide + PSMA PET-guided targeted radiation for BCR (Phase 3)
• NCT05939414 - 177Lu-vipivotide tetraxetan vs Observation in PSMA+ oligometastatic prostate cancer (Phase 3)
• NCT06276465 - Darolutamide ± radiation for CRPC with metastases on functional imaging (Phase 3)

Localized / Post-Surgery

• NCT05116475 - Darolutamide + ADT + radiation in newly diagnosed prostate cancer with limited metastases (Phase 3)
• NCT06274047 - PROSTATE-IQ: Personalized apalutamide treatment post-operative (Phase 3)
• NCT03678025 - Standard systemic therapy ± definitive treatment in metastatic prostate cancer (Phase 3)
• NCT05946213 - Shorter duration vs usual radiation in high-risk prostate cancer (Phase 3)

Novel Approaches

• Bispecific T-cell engagers: Xaluritamig (STEAP1×CD3) and pasritamig (PSMA×CD3) — first bispecifics reaching Phase 3 in prostate cancer, targeting mCRPC after AR therapy and chemotherapy
• PSMA radioligand therapy expansion: Moving from mCRPC to mHSPC (PEACE6) and oligometastatic settings
• AR degraders / novel AR targets: Opevesostat (CYP11A1), mevrometostat (EZH2), rezvilutamide — targeting AR signaling through new mechanisms
• PSMA PET-guided treatment: Multiple Phase 3 trials using PSMA PET to guide radiation, surgery, and systemic therapy decisions

Frequently Asked Questions